Pacira BioSciences Inc (PCRX)
16.57
-0.03
(-0.18%)
USD |
NASDAQ |
Nov 01, 16:00
16.55
-0.02
(-0.12%)
After-Hours: 20:00
Pacira BioSciences Revenue (Quarterly): 178.02M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 178.02M |
| March 31, 2024 | 167.12M |
| December 31, 2023 | 181.24M |
| September 30, 2023 | 163.93M |
| June 30, 2023 | 169.47M |
| March 31, 2023 | 160.34M |
| December 31, 2022 | 171.96M |
| September 30, 2022 | 167.47M |
| June 30, 2022 | 169.41M |
| March 31, 2022 | 157.99M |
| December 31, 2021 | 159.19M |
| September 30, 2021 | 127.72M |
| June 30, 2021 | 135.59M |
| March 31, 2021 | 119.03M |
| December 31, 2020 | 130.97M |
| September 30, 2020 | 117.48M |
| June 30, 2020 | 75.50M |
| March 31, 2020 | 105.68M |
| December 31, 2019 | 122.42M |
| September 30, 2019 | 104.68M |
| June 30, 2019 | 102.60M |
| March 31, 2019 | 91.31M |
| December 31, 2018 | 95.11M |
| September 30, 2018 | 83.45M |
| June 30, 2018 | 84.11M |
| Date | Value |
|---|---|
| March 31, 2018 | 74.61M |
| December 31, 2017 | 79.08M |
| September 30, 2017 | 67.34M |
| June 30, 2017 | 70.93M |
| March 31, 2017 | 69.28M |
| December 31, 2016 | 72.90M |
| September 30, 2016 | 68.36M |
| June 30, 2016 | 69.64M |
| March 31, 2016 | 65.47M |
| December 31, 2015 | 69.32M |
| September 30, 2015 | 62.21M |
| June 30, 2015 | 59.15M |
| March 31, 2015 | 58.32M |
| December 31, 2014 | 61.79M |
| September 30, 2014 | 52.05M |
| June 30, 2014 | 47.16M |
| March 31, 2014 | 36.66M |
| December 31, 2013 | 33.56M |
| September 30, 2013 | 23.26M |
| June 30, 2013 | 17.14M |
| March 31, 2013 | 11.59M |
| December 31, 2012 | 10.45M |
| September 30, 2012 | 8.486M |
| June 30, 2012 | 12.34M |
| March 31, 2012 | 7.804M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
75.50M
Minimum
Jun 2020
181.24M
Maximum
Dec 2023
146.34M
Average
159.19M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Cyclo Therapeutics Inc | 0.1231M |
| Revance Therapeutics Inc | 65.39M |
| NovaBay Pharmaceuticals Inc | 2.40M |
| Palatin Technologies Inc | 0.35M |
| iBio Inc | 0.175M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 18.89M |
| Total Expenses (Quarterly) | 147.05M |
| EPS Diluted (Quarterly) | 0.39 |
| Enterprise Value | 949.40M |
| Gross Profit Margin (Quarterly) | 75.14% |
| Profit Margin (Quarterly) | 10.61% |
| Earnings Yield | 8.03% |
| Operating Earnings Yield | 10.91% |
| Normalized Earnings Yield | 8.025 |